US38246G1085
US38246G1085
GoodRx Holdings, Inc.
Loading chart...
Valuation & History
Quarterly trend of key valuation metrics
| Metric | Current (TTM) TTM Baseline | Q2 '26 30.06.2026 | Q1 '26 31.03.2026 | Q4 '25 31.12.2025 |
|---|---|---|---|---|
Market & Enterprise Value | ||||
Market Cap | 1.17B EUR | 979.57M EUR | 661.65M EUR | 924.25M EUR |
Enterprise Value | 1.39B EUR | 1.22B EUR | 967.29M EUR | 1.21B EUR |
Valuation Multiples | ||||
Trailing P/E | 68.6x | 60.28x | 32.19x | 47.67x |
Forward P/E | 9.67x | -- | -- | -- |
Price to Sales | 1.49x | 1.25x | 0.84x | 1.56x |
Price to Book | 1.8x | 1.51x | 1.06x | 1.5x |
EV/Revenue | 1.77x | 1.56x | 1.23x | 2.03x |
EV/EBITDA | 12.77x | 7.16x | 5.58x | 8.85x |
Price to FCF (P/FCF) | 10.4x | 7.44x | 6.85x | 8.69x |
EV/FCF | 12.35x | 9.28x | 10.02x | 11.33x |
FCF Yield | 9.61% | 13.44% | 14.59% | 11.51% |